| This week's sponsor is Premier Research. | |  | >From Lab to Bedside: The Latest Rare Oncology Drug Research
Study of rare cancers demands immersion in dual indications where strategies often don't mesh. Attend our Feb. 28 webinar for fresh insights on speeding development of new drugs. Register now. Premier Research. It's what we do. Best. |
Featured Story | | | Monday, February 13, 2017 VenBio has criticized the timing and terms of Immunomedics’ licensing deal with Seattle Genetics. The investment fund has accused Immunomedics of rushing through a “poorly constructed deal” to sway shareholder opinion ahead of the upcoming fight for control of the biotech’s board. |
|
|
| This week's sponsor is Charles River. | | Webinar: When to Add PDX Models into Your Oncology Program: IO and non-IO?
Could PDX be the most cost-effective tool for targeted therapies in cancer? How can PDX be incorporated into an immuno-oncology program? Can clinical biomarkers be identified using these models?
Just a few of the questions that we'll discuss in our upcoming webinar providing an overview of our extensive experience with PDX models and best ways to use in your preclinical strategy. Join us. |
Top Stories Monday, February 13, 2017 Positive results in a first crop of patients treated with its dementia drug have encouraged Axovant to start preparing for a phase 3 study. Monday, February 13, 2017 Johnson & Johnson has outlicensed its portfolio of hypoxia-inducible factor to Cambridge, Massachusetts-based Akebia as the biotech boosts its early-stage pipeline. Monday, February 13, 2017 An aging population, an ever increasing amount of time viewing digital devices and a growing trend in eye diseases are all factors expected to fuel a global increase in Dry Eye Disease. Monday, February 13, 2017 Ferring Pharmaceuticals has struck a deal with Foresee Pharmaceuticals. The agreement will see Ferring fund development of a long-duration peptide drug based on Foresee’s delivery technology and potentially pick up the resulting asset if it meets expectations. Monday, February 13, 2017 A protein called PTEN is often called an “anticancer” protein, because it prevents tumor cells from growing out of control. Scientists at Cold Spring Harbor Laboratory have discovered that another protein protects PTEN, and that a deficiency in this protective mechanism could be the driving force behind some cases of prostate cancer, lung cancer and other tumor types. Monday, February 13, 2017 Last year, Stada weighed a buyout to fend off an activist shareholder. Now, nearly six months after touting a proxy battle victory, it’s weighing offers—and this time may find itself at the center of a bidding war. | This week's sponsor is Destination Medical Center. | |  | Destination Medical Center (DMC) is a 20-year, $5.6 billion economic development plan set to transform Rochester, MN. DMC and Mayo Clinic are accelerating new advancements in life science research, medical technology, patient care, and education. |
| | | Inovio and ApolloBio penned a $50 million development and sales deal for HPV pre-cancer immunotherapy VGX-3100 in China. Release Sage Therapeutics will push on with SAGE-217 in a placebo-controlled midstage test in major depressive disorder after seeing "positive signals" from a small, open-label trial. Statement Alzheon is set to post new data and analyses for ALZ-801 at the upcoming International Conference on Alzheimer’s and Parkinson’s Disease. Release | |
|
Resources Sponsored By: Veeva Learn over a dozen best practices for deploying a global content system. Read Whitepaper. Sponsored By: Veeva Gartner provides insightful research on preparing for IDMP compliance. Read Whitepaper. Sponsored By: Veeva Learn How to Create a Unified RIM Environment for IDMP. Find out. Sponsored By: Veeva The largest survey of TMF owners reveals drivers and trends in improving inspection readiness and shortening trial time. Sponsored By: Salesforce Learn how the healthcare and life science industry is using agile application development to drive innovation and accelerate their business with the Salesforce Platform. Presented by: Patheon Can you avoid a risky trial-and-error approach to find the right path for your poorly soluble molecule by utilizing a CDMO? Download this complimentary Whitepaper to learn more! | 
